National Institute on Drug Abuse; Notice of Closed Meeting

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published

October 14, 2022

Issuing agencies

Health and Human Services DepartmentNational Institutes of Health

Full Text

<html>
<head>
<title>Federal Register, Volume 87 Issue 198 (Friday, October 14, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 198 (Friday, October 14, 2022)]
[Notices]
[Pages 62433-62434]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-22361]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Blueprint MedTech (BPMT) Biocompatibility, 
Sterilization, and Animal Studies.
    Date: November 15, 2022.
    Time: 1:00 p.m. to 2:30 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review 
Officer, Scientific Review

[[Page 62434]]

Branch, Division of Extramural Research, National Institute on Drug 
Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 
20892, (301) 827-4471, <a href="/cdn-cgi/l/email-protection#beccdfd3dfdadfd0d7ccfed3dfd7d290d0d7d690d9d1c8"><span class="__cf_email__" data-cfemail="5022313d3134313e3922103d31393c7e3e39387e373f26">[email&#160;protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: October 11, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-22361 Filed 10-13-22; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>

View on FederalRegister.gov →Plain-text source

Indexed from Federal Register on October 14, 2022.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.